Zelira Therapeutics Limited

ASX:ZLD Stock Report

Market Cap: AU$7.9m

Zelira Therapeutics Past Earnings Performance

Past criteria checks 0/6

Zelira Therapeutics's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 3.5% per year.

Key information

-41.7%

Earnings growth rate

-20.6%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate-3.5%
Return on equityn/a
Net Margin-38,513.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Jan 19
Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Sep 25
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Jun 03
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Dec 31
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Revenue & Expenses Breakdown

How Zelira Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:ZLD Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-3723
31 Mar 240-3632
31 Dec 230-3641
30 Sep 230-2141
30 Jun 230-651
31 Mar 231-882
31 Dec 221-10102
30 Sep 221-11112
30 Jun 222-12121
31 Mar 221-11101
31 Dec 211-1081
30 Sep 211-982
30 Jun 211-972
31 Mar 210-863
31 Dec 200-854
30 Sep 200-854
30 Jun 200-744
31 Mar 200-633
31 Dec 191-433
30 Sep 191-423
30 Jun 191-422
31 Mar 191-312
31 Dec 180-312
30 Sep 180-312
30 Jun 180-212
31 Mar 180-212
31 Dec 170-211
30 Sep 170-411
30 Jun 170-621
31 Dec 160-520
30 Jun 160000

Quality Earnings: ZLD is currently unprofitable.

Growing Profit Margin: ZLD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

Accelerating Growth: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Return on Equity

High ROE: ZLD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies